Trial Profile
A Phase II Study of Bi-weekly XELOX with Bevacizumab for patient with Metastatic Colorectal Cancer as first-line chemotherapy
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 04 Apr 2022
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Capecitabine; Irinotecan; Oxaliplatin
- Indications Colorectal cancer
- Focus Therapeutic Use
- 28 Mar 2022 Status changed from recruiting to discontinued.
- 20 Mar 2013 New trial record